We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-3.25%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.29B
AUM Growth
-$158M
Cap. Flow
-$42M
Cap. Flow %
-1.83%
Top 10 Hldgs %
41.8%
Holding
210
New
13
Increased
53
Reduced
56
Closed
18

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$16.6M
2
ILMN icon
Illumina
ILMN
+$12.9M
3
HUM icon
Humana
HUM
+$10.1M
4
BIIB icon
Biogen
BIIB
+$7.74M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$6.2M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$18.7M
2
ABT icon
Abbott
ABT
+$15.4M
3
ARRY
Array Biopharma Inc
ARRY
+$15M
4
TMO icon
Thermo Fisher Scientific
TMO
+$13.4M
5
LLY icon
Eli Lilly
LLY
+$10.7M

Sector Composition

Rank Sector Weight
1 Healthcare 94.94%
2 Real Estate 3.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALKS icon
101
Alkermes
ALKS
$8.39B
$3.86M 0.17%
198,048
– –
BHC icon
102
Bausch Health
BHC
$2.25B
$3.69M 0.16%
168,812
– –
MPT
103
Medical Properties Trust
MPT
$2.81B
$3.66M 0.16%
187,063
– –
TAK icon
104
Takeda Pharmaceutical
TAK
$55.1B
$3.62M 0.16%
210,146
+32,018
+18% +$554K
STE icon
105
Steris
STE
$22.5B
$3.54M 0.15%
24,473
-4,508
-16% -$674K
XLRN
106
DELISTED
Acceleron Pharma
XLRN
$3.41M 0.15%
86,313
-102,075
-54% -$4.43M
AVDL
107
DELISTED
Avadel Pharmaceuticals
AVDL
$3.39M 0.15%
814,588
– –
EDIT icon
108
Editas Medicine
EDIT
$413M
$3.36M 0.15%
147,939
+102,950
+229% +$2.55M
CRL icon
109
Charles River Laboratories
CRL
$11.3B
$3.32M 0.14%
25,067
+10,900
+77% +$1.46M
DHC
110
Diversified Healthcare Trust
DHC
$2.17B
$3.31M 0.14%
357,720
– –
ALC icon
111
Alcon
ALC
$33.9B
$3.23M 0.14%
55,369
– –
IOVA icon
112
Iovance Biotherapeutics
IOVA
$2.09B
$3.19M 0.14%
175,012
-24,061
-12% -$532K
THC icon
113
Tenet Healthcare
THC
$21.8B
$3.12M 0.14%
141,136
-41,535
-23% -$885K
PTLA
114
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
$3.1M 0.14%
115,448
– –
INGN icon
115
Inogen
INGN
$174M
$2.95M 0.13%
61,526
+47,526
+339% +$2.48M
INSM icon
116
Insmed
INSM
$22B
$2.91M 0.13%
+164,786
New +$3.18M
DGX icon
117
Quest Diagnostics
DGX
$25.9B
$2.78M 0.12%
26,012
– –
CAH icon
118
Cardinal Health
CAH
$53.2B
$2.75M 0.12%
58,241
+51,941
+824% +$2.37M
ARDX icon
119
Ardelyx
ARDX
$1.25B
$2.74M 0.12%
582,698
-56,672
-9% -$197K
A icon
120
Agilent Technologies
A
$39.2B
$2.61M 0.11%
34,025
+425
+1% +$30.7K
FATE icon
121
Fate Therapeutics
FATE
$293M
$2.57M 0.11%
165,672
+141,293
+580% +$2.71M
WMGI
122
DELISTED
Wright Medical Group Inc
WMGI
$2.56M 0.11%
124,006
+55,500
+81% +$1.32M
PACB icon
123
Pacific Biosciences
PACB
$460M
$2.56M 0.11%
+495,495
New +$2.77M
FOLD
124
DELISTED
Amicus Therapeutics
FOLD
$2.52M 0.11%
314,597
– –
WVE icon
125
Wave Life Sciences
WVE
$1.11B
$2.52M 0.11%
122,551
+66,596
+119% +$1.53M
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q3 2019 Portfolio in Review

As of Q3 2019, Tekla Capital Management held 210 positions worth $2.29B, down 6.5% from $2.45B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Tekla Capital Management's Q3 2019 filing shows 13 new, 53 increased, 56 reduced and 18 closed positions. Its largest new stake was Insmed: 164,786 shares worth $2.91M. The largest sale was Amgen, an estimated $18.7M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 95% a quarter earlier, followed by Real Estate.

  • Tekla Capital Management's largest Q3 2019 buy was Insmed: 164,786 shares worth $2.91M.
  • Tekla Capital Management added most to Merck in Q3 2019, an estimated $16.6M increase.
  • Tekla Capital Management's biggest Q3 2019 reduction was Amgen, cutting an estimated $18.7M.
  • Tekla Capital Management fully exited Array Biopharma Inc in Q3 2019, selling an estimated $15M.
  • Tekla Capital Management's ten largest holdings make up 42% of its $2.29B portfolio in Q3 2019.
  • Tekla Capital Management opened 13 new positions and closed 18 in Q3 2019.
  • Tekla Capital Management's portfolio value fell 6.5% quarter-over-quarter to $2.29B.

Based on Tekla Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.